Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 394871, 8 pages
http://dx.doi.org/10.1155/2015/394871
Research Article

Moderate Dietary Supplementation with Omega-3 Fatty Acids Does Not Impact Plasma Von Willebrand Factor Profile in Mildly Hypertensive Subjects

1Inflammation and Healing Research Cluster, University of the Sunshine Coast, Maroochydore, 4556 QLD, Australia
2School of Health and Sport Sciences, University of the Sunshine Coast, Maroochydore, 4556 QLD, Australia
3School of Science and Engineering, University of the Sunshine Coast, Maroochydore, 4556 QLD, Australia
4School of Nursing and Midwifery, University of the Sunshine Coast, Maroochydore, 4556 QLD, Australia

Received 13 July 2014; Revised 28 September 2014; Accepted 28 October 2014

Academic Editor: Karsten Weylandt

Copyright © 2015 Corinna S. Bürgin-Maunder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) have blood pressure lowering and antithrombotic effects, which may benefit hypertensive patients. Increased plasma concentration of von Willebrand factor (vWF), a procoagulant glycoprotein, has been identified in patients with severe hypertension, with some, but not all studies showing an increase with mild hypertension. In this study, we determined the plasma concentration, multimer distribution, and collagen binding activity of vWF in subjects with mild hypertension and determined whether these parameters might improve after dietary supplementation with moderate amounts of LC n-3 PUFAs. Hypertensive and normotensive subjects were randomized to 12-week treatment with LC n-3 PUFAs (2.52 g/day) or placebo (canola oil). Home blood pressure measurements were recorded daily, and blood samples were collected every 3 weeks. LC n-3 PUFAs increased the n-3 index to cardioprotective levels (>8%). Plasma concentration, multimer distribution, and collagen binding activity of vWF were not reduced by LC n-3 PUFA treatment. We conclude that, at the concentration and duration used in this study, benefits of LC n-3 PUFAs in subjects with mild hypertension are not associated with a direct effect on vWF concentration or function. This trial is registered with the Australian New Zealand Clinical Trials Registry ACTRN12610000713099.